Navigation Links
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Date:6/24/2008

guide-lines for diagnosis and treatment of skin cancer, and it provides direction, coordination and organizations of clinical, therapeutic, and experimental trials.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
2. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Genta Receives Key Patent Related to Oral Gallium Compound G4544
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Genta Clinical Programs Featured at American Society of Hematology Meeting
11. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) ... secured $1 million in 12% per annum short term ... is an initial drawdown of $500,000, with accrued interest ... of $500,000 with accrued interest and principal repayable in ... Company becoming cashflow positive for any calendar month prior ...
(Date:12/16/2009)... EuroPharma, Inc. signs exclusive multi-year ... of super absorbency BCM-95® curcumin and specialized ... The exclusive distribution territory for these clinically-studied ... channel and professional channel, which includes allopathic ... BCM-95® is a highly absorbable curcumin. ...
(Date:12/16/2009)... 16 RealMed has been ranked ... the 2009 Top 20 Best in ... report. RealMed is a dynamic revenue cycle ... processing between healthcare providers and all ... firm specializing in vendor performance measurement in ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3New impact factor of European Urology underlines journals outstanding position 50912 1New impact factor of European Urology underlines journals outstanding position 50912 2Food crisis and global health workshop July 14 16 50910 1Coralline algae in the Mediterranean lost their tropical element between 5 and 7 million years ago 9137 1Coralline algae in the Mediterranean lost their tropical element between 5 and 7 million years ago 9137 2
(Date:12/16/2009)... a result of C3: Colorectal Cancer Coalition,s advocacy efforts, ... program is included in the final Fiscal Year 2010 ... program will research cancers, like colorectal cancer, that are ... cancer research programs run by the U.S. Army Medical ... million in funding for this new cancer research program ...
(Date:12/16/2009)... Study suggests it plays a role in reducing inflammation ... -- A gene variant that plays a role in ... asthma as well as adults who smoke. , Researchers ... the MMP12 gene had a lower risk of developing ... brought on by smoking. , "The gene seems to ...
(Date:12/16/2009)... WASHINGTON The omega-3 essential fatty acids commonly ... avoid sensory overload, according to research published by ... omega-3s to the information-processing problems found in people ... Huntington,s disease; and other afflictions of the nervous ... journal Behavioral Neuroscience , provides more evidence ...
(Date:12/16/2009)... caution, though, that no direct link has been found, ... bacteria in food -- commonly linked to food poisoning ... might also be the cause of some urinary tract ... the bacteria in chicken from stores and restaurants and ... evidence that the germs were transmitted directly to the ...
(Date:12/16/2009)... Age should not be determining factor for use, expert ... people with heart failure are much less likely to ... a new study. , The study included 4,685 people, ... device and had a left ventricular fraction (a measure ... less. , During a three-year period, those who were ...
Breaking Medicine News(10 mins):Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:Implanted Defibrillator Might Extend Life 2
... been a lot of research on the potential link between ... the more infections you have throughout your life, the more ... from the Johannes Gutenberg University in Mainz, Germany, looked at ... blood for the common bacteria and viruses to see if ...
... Research carried out in England has buttressed the suggestion ... of Alzheimer's disease.Doctors at the National Institute on Aging ... who suffered head injuries// during World War II. ... injuries were twice as likely to develop Alzheimer's while ...
... have the greatest increase in bone mineral after the growth ... exercise are in danger of suffering broken bones in later ... their skeleton during a vital two-year window before puberty, which ... to be between 10 and 12 and in boys it ...
... to diagnose heart problems. A new method of scanning ... a useful alternative to conventional methods for diagnosing heart ... the cause of heart disease involves injecting a dye ... at University of Cleavland have learned that using magnetic ...
... a natural lens promises to make cataract patients’ eyesight ... young.The device, which is being developed by Jin-Hui Shen, ... Nashville, Tennessee, contains six overlapping lenses.// ,As the ... patients to focus on closer objects.,Millions of people are ...
... The way you talk to your baby may be more ... the youngster master the language.There has been some controversy swirling ... one.// Some have suggested that normal grownup talk is actually ... researchers took one step towards settling this issue once and ...
Other Medicine News:Health News:Artificial lenses- Boon to cataract patients 2
... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...
... Knee design includes several innovative ... porous coating option for stable ... unique bone preserving posterior stabilizing ... to maximize range of motion, ...
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
Scorpio CR Knee is designed to address normal knee kinematics, range of motion (ROM) and polyethylene wear....
Medicine Products: